Imatinib Plus Artemether-Lumefantrine for Uncomplicated Malaria
Treatments studied
Part of Infections clinical trials.
This trial tests whether adding a cancer drug called imatinib to standard malaria treatment works better and is safe. Researchers will enroll adults and children with uncomplicated malaria caused by P. falciparum parasites and monitor them in the hospital for 2–3 days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with uncomplicated (not severe) P. falciparum malaria with a parasite count of at least 5,000 parasites per microliter of blood
- Adults aged 18–55 (non-pregnant women must use active birth control) OR children aged 12 months to under 18 years with a parent/guardian's consent
- Able to stay in the hospital for 48–72 hours and attend follow-up visits
- No anti-malarial medications in the past 4 weeks (or 6 weeks for children)
- Normal blood counts, liver, kidney, and heart function (confirmed by blood tests)
- No other serious infections, heart disease, or use of certain medications that interact with the trial drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well malaria treatments work in Ethiopia. It aims to find the best medicines for uncomplicated malaria caused by certain parasites, helping patients recover fully and preventing future drug resistance.
This study compares a combination of three medicines to treat uncomplicated malaria, to see if it works as well and is as well tolerated as a two-medicine combination. You may join if you have a specific type of malaria infection in a mild form and meet safety requirements.
This trial studies how well and how safely different anti-malaria medicines work for people who have uncomplicated malaria caused by Plasmodium falciparum. You may be eligible if you have a confirmed infection with a certain parasite level and do not have signs of severe disease or major health conditions.
This study tests a new malaria treatment for children with mild (uncomplicated) malaria. The goal is to see if the treatment safely and effectively clears the infection.
This trial tests a medicine called tafenoquine, which is used to treat malaria. It aims to see how well it works in children with uncomplicated malaria, and participants will also receive standard malaria treatments.
This study tests a new malaria pill in adults with uncomplicated malaria (mild form). The pill aims to treat the infection, and participation involves monitoring and follow-up visits.
Hear when a new Malaria (Plasmodium Falciparum) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.